Spesolimab-sbzo for generalized pustular psoriasis
Customize your policy alerts
Sign up for healthspring Policy RX501.181 alerts
Get alerted when Policy RX501.181 changes without checking for updates manually.
Monitor payer policy activity
Medical-necessity coverage for spesolimab-sbzo (Spevigo) to treat generalized pustular psoriasis in eligible adults and pediatric patients; self-administered formulations are reviewed under the applicable pharmacy benefit plan.
The existing-flare criterion was revised to require moderate-to-severe generalized pustular psoriasis documented by at least one specified clinical measure.
A consensus statement from the National Psoriasis Foundation was added as a reference.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.